Public Health Reports / September-October 2005 / Volume 120 Pediatric asthma is a serious chronic illness affecting nine million children in the United States. 1 The Centers for Disease Control and Prevention (CDC) conduct national surveillance of asthma through the National Health Interview Survey (NHIS), the Behavioral Risk Factor Surveillance System (BRFSS), and several other national surveys of asthma health services utilization, as well as through asthma mortality reported through the National Vital Statistics System. [2] [3] [4] Although these data offer an important national perspective on asthma morbidity and mortality trends among children, the respective surveys are not designed to produce comparisons between states. Some states collect pediatric asthma prevalence information through the BRFSS or through hospitalization discharge data, but not all states collect this information and individual states may not collect this information consistently from year to year. 5 Consequently, few data are available to state health agencies and health plans regarding changes in statewide asthma prevalence or asthmarelated utilization.
Recognizing the dearth of statewide asthma prevalence information, the CDC recommended the development of asthma surveillance mechanisms within states to identify and monitor opportunities for intervention within states. [6] [7] [8] A recent policy initiative aimed at improving pediatric asthma outcomes recommended the development of a national asthma surveillance system, including surveillance systems that can identify high-risk areas within states. 9 One illustration is provided by a pilot asthma surveillance system in Maine, which was established based on inpatient and outpatient utilization from a sample of hospital service areas within the state, combined with patient and provider surveys. 10 While this study illustrated the feasibility of using administrative data for statewide asthma surveillance of severe asthma events, this demonstration was also reliant upon survey data and self-reported information on other aspects of asthma management.
Using existing information infrastructure such as Medicaid administrative claims is an alternative approach that would limit asthma surveillance program costs. Given that 20% of children younger than age 18 in the United States are enrolled in Medicaid, this approach has the additional benefit of addressing a substantial portion of the population-one for whom states have responsibility for medical care costs. 11 Earlier asthma surveillance work using Medicaid data has demonstrated the basic application of this concept, although methodologies vary considerably. A study in North Carolina used Medicaid claims to identify children having asthma, based on primary and secondary diagnosis codes reported on inpatient and outpatient claims, as well as any evidence of asthma medication use. 12 Results from this study suggest a two-fold range of prevalence estimates, depending on whether medication data were taken into consideration. Similarly, a study of children enrolled in the Connecticut Medicaid program, which used another case classification definition, found up to a two-fold difference in asthma prevalence, depending upon whether use of asthma medications was considered. 13 Both of these earlier studies have included prevalence estimates for children younger than 3 years of age, but other studies have shown that the asthma phenotype known as "early transient wheezing" among very young children characteristically resolves itself and is not associated with elevated risk of asthma by 6 years of age. [14] [15] [16] An assumption underlying asthma surveillance using administrative claims data is that the method provides reliable estimates. Absent detailed information from medical records, administrative claims data provide a relatively limited set of diagnosis, pharmaceutical, and procedure information upon which an asthma case can be identified. One concern is the use of criteria that allow a single encounter with a diagnosis code for asthma to constitute sufficient evidence to be counted as a case. It is possible that these situations actually reflect an office visit at which asthma was ruled out. Similarly, a single dispensing event for a medication used in the treatment of asthma may, or may not, be reflective of an asthma case. A solitary claim for an asthma-related service may simply be an artifact of cross-sectional sample of claims data that does not reflect a longitudinal record of patient information.
Very little published information is available regarding the consistency of asthma classification over time using administrative claims data. The degree of asthma health services utilization among children with asthma has been shown previously to vary from year to year. In a study of asthma emergency department (ED) and inpatient utilization among Medicaid children, many high-frequency users were found to have low utilization for the same services in the following year. 17 Although previous results have described annual variations in asthma prevalence among children enrolled in Medicaid at a population level, 18 the degree to which an individual child is consistently classified as having asthma from year to year based on administrative data is unknown. The consistency of asthma classification over time is an important consideration in asthma outcomes studies and quality of care assessments using administrative data classification criteria such as the National Committee on Quality Assurance's (NCQA) Healthplan Employer Data and Information Set (HEDIS) methodology. 19 With those issues in mind, the objectives of our study were to (1) describe pediatric asthma prevalence determined from Medicaid administrative claims and assess the degree to which asthma case definition influences prevalence, and (2) quantify the concordance in asthma classification for children over a two-year period and identify characteristics associated with a high degree of year-to-year agreement in asthma classification.
METHODS

Study population
This study was based on a retrospective analysis of Michigan Medicaid administrative data for services furnished during calendar years [2001] [2002] . In Michigan, low income children younger than 1 year (Ͻ185% of the federal poverty level) and those from 1 to 18 years of age (Ͻ150% of the federal poverty level) are eligible for Medicaid, as are those who are blind or have a disability. We obtained data from Medicaid program enrollment files, fee-for-service health services claims, and encounter records for all managed care plan enrollees, including those with dual Title V (i.e., Children with Special Health Care Needs) eligibility. Data for children enrolled in the State Children's Health Insurance Program (SCHIP) were not available and therefore could not be included in this analysis. A total of 791,678 children 18 years of age and younger were enrolled in the Michigan Medicaid program for calendar years [2001] [2002] . Since prior studies suggest that some asthma among children 3 years of age and younger resolves itself over time, we wished to contrast prevalence and year-to-year concordance between younger and older children and therefore included all children younger than 18 years of age in our study sample.
Of these children, we included only beneficiaries for whom complete administrative claims were available; consequently, we included children who were continuously enrolled over the two-year study period (with an allowance for up to a one-month gap in enrollment each year), who were fully covered by Medicaid, and who did not have any other sources of health insurance in addition to Medicaid. In total, the study sample consisted of 357,729 children (45.2% of the initial population). Claims for inpatient, ED, and outpatient health services for these children were obtained for services with primary ICD-9 CM diagnosis codes of 493.0 through 493.9. 19 In addition, asthma-related pharmacy claims were identified using National Drug Codes as defined by HEDIS specifications. Asthma medications included shortand long-acting adrenergic bronchodilators, bronchodilator combinations, inhaled anticholinergics, inhaled corticosteroids, cromolyn sodium and nedocromil, leukotriene modifiers and methylxanthines; a complete reference is available from NCQA. 20 Demographic data and enrollment status were obtained from Medicaid program enrollment files including date of birth, gender, race/ethnicity, program of enrollment, and county of residence. The county of beneficiary residence was classified as being urban or non-urban, based on presence of a metropolitan statistical area (MSA); as defined by the U.S. Census Bureau, each MSA must have at least one urbanized area of 50,000 or more inhabitants and comprise one or more entire county. 21 Disability status was determined from each child's Medicaid program of enrollment; children eligible for blind or disabled benefits or those eligible under Title V for benefits through the Children with Special Health Care Needs program were designated as "disabled."
Outcomes measured
Asthma cases were identified based upon claims for inpatient, outpatient, and ED services (not including procedures or laboratory claims), and medication dispensing events using six alternative definitions for comparative purposes, as summarized in the Figure. The first definition required a child to have at least one claim with an asthma primary diagnosis (i.e., inpatient, ED, or outpatient services) within a calendar year. Cases were also identified using two criteria based on asthma medication dispensing events; a child was required to have at least one annual asthma medication dispensing event (Definition 2) or, alternatively, have at least four asthma medication dispensing events annually (Definition 3). Two additional case definitions combined criteria based upon a reported asthma diagnosis as well as asthma medications. The first of these (Definition 4) required either at least one claim with an asthma diagnosis, or at least one asthma medication dispensing event; we also identified cases with at least one claim with an asthma diagnosis, or at least four asthma medication dispensing events (Definition 5). Lastly, we classified children with evidence of persistent asthma using HEDIS criteria 19 (Definition 6), a case definition which is used extensively by Medicaid and commercial health plans and in asthma outcomes studies. Although HEDIS criteria specify children 5 years of age and older, we included all children under 18 years of age to assess variations in the prevalence of asthma among very young children using alternative definitions. We also wished to assess the degree to which young children are more likely to have an asthma-related visit in one year but not subsequently, consistent with a visit to rule out asthma.
Statistical methods
We computed univariate descriptive statistics and performed chi-square tests to assess associations between each type of asthma utilization and demographic characteristics of the child. HEDIS persistent asthma classification agreement between the two study years was assessed by age based on the kappa statistic. 22 We used multivariate logistic regression models to estimate the odds of having persistent asthma, Public Health Reports / September-October 2005 / Volume 120 taking into account prior year asthma utilization and controlling for age, gender, race, and urban residence. All statistical analyses were conducted using the Statistical Analysis System (SAS). 23 
Figure. Six alternative asthma case definitions
RESULTS
Demographic characteristics of Michigan Medicaid enrollees 0-18 years of age during the 2001-2002 study period are illustrated in Table 1 , contrasting children in our sample with those excluded due to discontinuous enrollment and/ or having other health insurance in addition to Medicaid. Our sample of children with continuous enrollment and no other insurance tended to include a greater proportion of children who were from 5-14 years of age, black race, lived in urban areas, and had a disability (pϽ.001). Overall, 14.9% of children had at least one claim for an asthma-related service in 2001, while 13.7% had some asthma utilization in 2002. The most common form of asthma utilization was for pharmacy services; 14.2% of children had at least one asthma medication dispensing event in 2001, while 13.0% had asthma medication use in 2002. Table 2 illustrates that the proportion of children with any claims evidence of asthma inpatient, ED, outpatient, or pharmacy utilization during each year varied significantly by age, gender, race, urban residence, and disability status of child (pϽ.0001). The highest proportion of children with asthma utilization was among those younger than 5 years old; this finding was consistent for each type of utilization and across both years. Males were more likely to have asthma utilization than females for each type of asthma service in both years.
White children consistently had higher likelihood of outpatient and pharmacy utilization, whereas black children were more likely to use emergency department or inpatient services for asthma. A similar pattern was observed among urban children, who were less likely to use outpatient and pharmacy but more likely to use emergency department or inpatient services for asthma. Children with disabilities had sharply higher likelihood of asthma utilization of all types in both years.
Applying alternative asthma case definitions yielded widely varying estimates of asthma prevalence, depending upon the criteria used (Table 3 ). The highest overall prevalence estimates were observed based on any claims evidence of asthma (14.9% in 2001) , and the lowest estimate was 3.7%, based on four or more asthma medications (2001). Estimates of asthma prevalence varied significantly by age of child as well as case definition (pϽ0.001). Asthma prevalence estimates were highest among children younger than 5 years of age for each case definition and for both years. The highest prevalence estimate for these children was based upon the case definition of having at least one asthma claim of any type; this definition suggests that 23.6% of children younger than 5 years had asthma in 2001 (19.1% in 2002) . Asthma prevalence for each age group was substantially lower when these cases were restricted to include only those with at least four asthma medication dispensing events. Using this case definition, prevalence ranged from 10.4% for children younger than 5 years to 6.0% for 15-18-year-olds and 7.5% over all age groups. Similar, but somewhat lower, prevalence estimates were observed based on criteria requiring an asthma diagnosis on claims (6.4% over all ages in 2001). The lowest asthma prevalence estimates in both years were observed using the criteria of at least four asthma medications; 3.7% of all children met this case definition in 2001 (3.8% in 2002) with 15-18-year-olds having the lowest rate using these criteria (pϽ0.001). While overall asthma prevalence typically decreased from 2001 to 2002 (with the exception of the at least four asthma medications case definition), rates for several case definitions increased among children 5-9 and 10-14 years old.
Most children (56%) with at least one asthma claim in 2001 also had at least one claim the following year, while the balance (44%) had no asthma-related claims. Asthma classification concordance between the two study years was found to vary considerably, depending upon the case definition used. Among children having no asthma claims in 2001, 6% had at least one asthma claim in the following year. Table 4 illustrates the agreement (kappa) between each asthma case definition in 2001 and 2002. The highlighted diagonal shows the agreement for each case definition using identical classification criteria in both years.
Over all age categories, the greatest agreement between cases identically defined in 2001 and 2002 was for those that were categorized based on at least four asthma medications (0.58), while the poorest year-to-year agreement (0.41) was for those having at least one claim with an asthma diagnosis (difference statistically significant, pՅ0.05). Persistent asthma cases in 2001 had moderate (0.54) agreement with 2002 persistent asthma cases and had the lowest agreement with 2002 cases classified using either the at least one medication or at least one asthma claim of any type criteria (0.38). For cases classified using HEDIS persistent asthma criteria, there was moderate classification agreement between the two years, but the strength of agreement was significantly lower (pՅ0.05) for children younger than 5 years (0.44) compared to 5-9-year-olds (0.57), 10-14-year-olds (0.60), and 15-18-year-olds (0.59). Similar patterns in year-to-year agree- NOTES: The highlighted diagonal shows the agreement for each case definition using identical classification criteria in both years. Results for case definition 5 were nearly identical to those for case definition 6, and were therefore omitted.
ment levels by age were also observed for the other asthma case definitions. Table 5 
DISCUSSION
Our findings demonstrate that using Medicaid administrative claims to estimate statewide asthma prevalence may yield widely variable estimates, depending upon the asthma case definition used, with moderate year-to-year classification agreement. We found that asthma prevalence estimates based upon our least restrictive case definition criteria were more than four times the rates observed using our most restrictive definition, and that the variation was greatest among the youngest children. Despite the differences observed in prevalence estimates between alternative case definitions, we found that prevalence varied in a similar manner across demographic characteristics within each case definition. Our findings also suggest that while children younger than 5 years frequently use health services that result in claims with an asthma diagnosis, these children are much less likely to have some form of claims evidence of asthma in the subsequent year, possibly due to visits being made to rule out asthma. Regardless of case definition, asthma cases identified using a claims set from a single year were often not classified as cases using identical criteria applied to claims for the subsequent year. This potential for misclassification could introduce substantial bias away from the null in studies that identify asthma cases in one year and assess asthma outcomes in a subsequent year. Our prevalence estimates are consistent with those reported in a previous study that assessed asthma prevalence using North Carolina Medicaid administrative claims for a single year. 12 That study (restricted to children 0-14 years old) found a prevalence of 6.1% based on claims with an asthma diagnosis; the comparable rate from our study (when our results are restricted to the comparable age range) was consistently 6.7% in both 2001 and 2002. The same study reported prevalence of 12.5% based on at least one asthma claim of any type (including asthma medications), compared to our findings of 15.6% in 2001 and 14.1% in 2002 for the comparable subset of our study population. Methodological differences in the North Carolina study such as including children with discontinuous enrollment or having other potential sources of insurance and excluding managed care enrollees would tend to understate the prevalence estimates observed in that study. Our estimates of asthma prevalence are lower than those reported for children enrolled in the Connecticut Medicaid program, which estimated asthma prevalence in 2002 to be 8.1%, based on claims with a primary or secondary asthma diagnosis, and 17.9% when long-term controller medications were considered. 18 Regardless of case definition, we found that the prevalence of asthma was higher among children younger than 5 years, a finding that is consistent with previous studies based on Medicaid administrative claims. 12, 18 The apparent decrease in asthma prevalence from 2001 to 2002 is driven by decreased asthma utilization among our study sample and is consistent with results presented for the Connecticut Medicaid program, 18 although the underlying factors influencing the reduction in asthma health services utilization cannot be ascertained from these results.
While overall asthma prevalence remained steady using some case definitions (such as HEDIS persistent asthma), our findings regarding the moderate level of year-to-year agreement of asthma classification are especially important. HEDIS assessments of appropriate asthma medication use are widely employed by commercial and Medicaid health plans for quality assessments and accreditation, and these methods are being used with increasing frequency in asthma outcomes analyses using administrative claims. 13, 18, [24] [25] [26] Based upon our findings, we would expect that HEDIS rates of appropriate and preferred asthma medication use may be understated, given that many cases identified in the year prior to the measurement year may have little or no asthma utilization during the subsequent measurement year. Some discordance between the numerator and denominator may be the result of children making office visits to rule out asthma, may reflect children treated in one year who have responded well and who have successfully undergone a gradual stepwise reduction in treatment, 27, 28 may be a sign of transient wheezing asthma cases that have resolved themselves over time, [14] [15] [16] or may reflect those who are chronically undertreated and only sporadically appear in claims data for urgent events. Our findings that this discordance is particularly high among children younger than age 5 is consistent with the NCQA HEDIS specification that excludes children 4 years old and younger. 20 The results of this study do not necessarily suggest a change in the use of the HEDIS asthma performance measure as it is implemented for assessing health plan quality of care. We acknowledge that the HEDIS administrative claims definition of persistent asthma was not originally designed for surveillance purposes; however, this case definition has proven to be increasingly attractive to health services researchers and public health practitioners studying asthma among the insured population. 13, 18, 26, 29 It is not our intent to assess the validity of the HEDIS appropriate asthma medications measure, but rather to evaluate the claims-based case definition for use in asthma surveillance and the evaluation of interventions to reduce the burden of asthma. Given the year-to-year fluctuations described in our findings, we believe that caution should be used in applying the HEDIS definition of persistent asthma to asthma prevalence or outcomes studies.
Our findings suggest that the relatively high levels of agreement between 2001 and 2002 HEDIS persistent asthma classification may be reflective of children having at least four asthma medication dispensing events, since this definition is subsumed by the HEDIS persistent asthma definition and was found to have similar year-to-year agreement. Although the four or more asthma medication criterion had the best year-to-year concordance in our study, the degree to which these cases reflect persistent asthma cases using objective clinical criteria is not clear. There is some evidence from other research to suggest that the most reliable indicators of asthma from administrative data may be those based upon a combination of historical medical and current pharmaceutical asthma utilization. 30 Elsewhere, persistent asthma cases identified using NCQA HEDIS criteria have been shown to have fairly high sensitivity but lower specificity for distinguishing asthma severity among children. 31 There are several limitations to this study. Our findings are based upon administrative claims data for a continuously enrolled pediatric Medicaid population and may not be generalizable to adult populations, enrollees in private health insurance plans, or those with gaps in enrollment. Since it is possible for states to modify Medicaid eligibility criteria over time, it is important that longitudinal comparisons be based upon a sample of continuous enrollees. Although we did not have access to patient records in this study, other studies have shown high sensitivity and specificity for diagnoses obtained from administrative data among children with high-risk conditions including asthma, 32 and high predictive value among adolescents and adults with asthma. 33 In contrast, other findings suggest that administrative data have low sensitivity and high specificity among adults with asthma, although this study did not take asthma medication use into account. 34 There is some evidence to suggest that administrative data may understate asthma prevalence, since these data reflect only those individuals with health care provider contacts. Yeatts et al. found that 6% of adolescents with frequent wheezing had no physician diagnosis of asthma. 35 Finally, some medications used for asthma in children may be used for other respiratory disorders (i.e., cystic fibrosis or bronchiolitis). As a result, we may be overestimating the use of these medications for asthma, and thus, overestimating asthma severity.
Despite limitations, we feel that statewide Medicaid administrative data can be used to complement national asthma surveillance activities and can feasibly support asthma surveillance and program evaluation programs within individual states. Using administrative claims such as those maintained by state Medicaid programs, variations in asthma prevalence and corresponding health care utilization can be measured for small geographic areas within states, which will assist in identifying areas of greatest need, targeting resources and services, and evaluating the impact of programmatic activities. Small area data are also useful for examining the impact of local level environmental and policy changes on asthma rates, generating hypotheses for further study.
Given the wide variations in prevalence estimates and year-to-year concordance observed between case definitions, caution must be exercised in asthma studies based upon administrative claims data. The NCQA HEDIS persistent asthma case definition is an attractive option, given that it can be applied based upon administrative data and it is extensively used by health plans. Use of this definition offers a mechanism to compare asthma prevalence between statewide Medicaid populations, as well as within a given state with rates computed by health plan enrollees. Although the HEDIS persistent asthma case definition may also be useful as a consistent measure of prevalence trends over time, our findings of poor year-to-year concordance suggest that it may not be well-suited to identifying changes in outcomes for enrollees with asthma in an intervention study if cases are identified in one year and outcomes measured in the following year. These findings underscore the importance of identifying enrollees with consistent claims evidence of asthma within each year of a study and the importance of using a control group in the evaluation of intervention efforts.
